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Abstract
Recent studies show a relationship between the deficit of vascular endothelial growth factor
(VEGF) and motoneuronal degeneration, such as that occurring in amyotrophic lateral scle-
rosis (ALS). VEGF delivery protects motoneurons from cell death and delayed neurodegen-
eration in animal models of ALS. Strikingly, extraocular motoneurons show lesser
vulnerability to neurodegeneration in ALS compared to other cranial or spinal motoneurons.
Therefore, the present study investigates possible differences in VEGF and its main recep-
tor VEGFR-2 or Flk-1 between extraocular and non-extraocular brainstem motoneurons.
We performed immunohistochemistry and Western blot to determine the presence of VEGF
and Flk-1 in rat motoneurons located in the three extraocular motor nuclei (abducens, troch-
lear and oculomotor) and to compare it to that observed in two other brainstem nuclei (hypo-
glossal and facial) that are vulnerable to degeneration. Extraocular motoneurons presented
higher amounts of VEGF and its receptor Flk-1 than other brainstem motoneurons, and thus
these molecules could be participating in their higher resistance to neurodegeneration. In
conclusion, we hypothesize that differences in VEGF availability and signaling could be a
contributing factor to the different susceptibility of extraocular motoneurons, when com-
pared with other motoneurons, in neurodegenerative diseases.
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by a progres-
sive loss of upper and lower motoneurons in the central nervous system. However, not all
motoneurons are equally vulnerable to the disease. Whilst most motoneuron pools are dam-
aged, motoneurons of the oculomotor system are resistant to neurodegeneration in ALS. At
early stages of the disease, a severe neuronal loss is consistently observed in the facial, trigemi-
nal and hypoglossal nuclei, producing profound deficits of tongue motility, dysphagia and dys-
arthria [1,2]. By contrast, the oculomotor, trochlear and abducens nuclei remain unaffected in
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human ALS and in animal models of ALS [1–4]. Unraveling the characteristics that distinguish
vulnerable from non-vulnerable motoneurons in ALS disease will allow a better understanding
of the mechanisms involved in neurodegeneration and, therefore, the development of new
therapeutic strategies.
Several aspects distinguish extraocular muscle motoneurons from other brainstem moto-
neurons. Thus, extraocular motoneurons are enriched in calcium buffering proteins, mainly
parvalbumin [2,5,6], which could provide them with a higher resistance to neurodegeneration
due to disruption of calcium homeostasis observed in ALS disease [7,8]. On the other hand,
previous studies have revealed that the relative abundance of the neuropeptide calcitonin
gene-related peptide (CGRP) in motoneurons predicts their vulnerability in ALS models, thus
suggesting that CGRP might be an autocrine or paracrine factor promoting motoneuron
degeneration. Motoneurons of the extraocular system show low expression of CGRP when
compared to other vulnerable motoneurons, like facial or spinal ones [9,10]. Another charac-
teristic that differentiates extraocular motoneurons from others is the presence of the specific
receptor for nerve growth factor (NGF), TrkA, in the adult animal [10–12]. Other cranial or
spinal motoneurons express the high affinity receptor for brain-derived neurotrophic factor
(BDNF), TrkB, or neurotrophin-3 (NT-3), TrkC, in the adult, but lack TrkA [13–16]. Extraoc-
ular motoneurons also express TrkB and TrkC [11]. Thus, the specific neurotrophic action of
NGF in ocular motoneurons could be also contributing to their higher resistance to neurode-
generation. However, clinical trials of neurotrophins application to patients led to variable
results and they did not reach the expected success [17].
The vascular endothelial growth factor (VEGF) has been proposed as a neurotrophic and
neuroprotective factor for motoneurons, since a decrease in VEGF supply has been related to
motoneuron degeneration in motor system diseases such as ALS [18,19]. VEGF has been clas-
sically a well-known angiogenic factor, but the fact that impairing VEGF production through
genetic manipulation results in degeneration of motoneurons, resembling ALS [20], has
revealed that the ability to produce endogenous VEGF may be important for maintaining the
health of motoneurons in the brainstem and spinal cord. In addition, VEGF delivery through
retrograde transport of a lentiviral vector injected into several muscles delays onset and pro-
longs the survival of SOD1G93A mice, an animal model of ALS [21], and its intracerebroventri-
cular infusion preserves neuromuscular junction in the SOD1G93A rat model of ALS [22].
These findings have increased the interest in evaluating the therapeutic potential of VEGF for
neurodegenerative disorders. VEGF is known to mediate its biological functions via activation
of the protein tyrosine kinase receptors, VEGF receptor 1 (VEGFR-1/Flt-1) and VEGFR-2
(KDR/Flk-1), although most evidence points to Flk-1 as the main receptor mediating VEGF
action in neuronal function [23,24].
Therefore, it would be interesting to explore whether the lesser vulnerability to degenera-
tion observed in extraocular motoneurons could be, at least in part, due to a higher amount of
VEGF. In order to achieve this goal, the presence of VEGF and its receptor Flk-1 was analyzed
by immunohistochemistry and Western blot in the extraocular motor nuclei, and compared
with that observed in other non-extraocular cranial motoneurons located in the facial and
hypoglossal nuclei, which are susceptible to neurodegeneration [3,4].
Materials and methods
Experiments were performed in adult Wistar rats in accordance with the guidelines of the
European Union (2010/63/EU) and Spanish law (R.D. 53/2013, BOE 34/11370-421) for the
use and care of laboratory animals. Surgical procedures used in this study were approved by
the ethics committee of Universidad de Sevilla.
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Immunohistochemistry
Adult rats (n = 9) were perfused transcardially under deep anesthesia (sodium pentobarbital,
50 mg/kg, i.p.) with 100 ml of physiological saline followed by 250 ml of 4% paraformaldehyde
in 0.1 M sodium phosphate buffer, pH 7.4 (PB). The brainstem was removed and cryopro-
tected by immersion in a solution of 30% sucrose in sodium phosphate-buffered saline (PBS)
until sinking. Tissue was then cut coronally in 50-μm-thick sections using a cryostat (Leica
CM1850, Wetzlar, Germany). Brainstem sections were divided in two series: one for VEGF
immunohistochemistry, and the other for Flk-1, selecting alternate sections for each series.
After washing in PBS, coronal sections containing the oculomotor, trochlear, abducens,
facial and hypoglossal nuclei were incubated in 1% sodium borohydride prepared in PBS for
10 minutes for antigen retrieval, and then rinsed again in PBS. Double immunofluorescence
was made for choline acetyltransferase (ChAT), the biosynthetic enzyme of acetylcholine,
therefore a general marker for motoneurons, that was used in this work to identify the brain-
stem motor nuclei, along with either VEGF or Flk-1, using TRICT, Cy2 or FITC as fluoro-
phores, respectively.
For VEGF immunohistochemistry, nonspecific binding was blocked by incubation for 45
minutes in a solution consisting of 10% normal horse serum in PBS with 0.01% Triton X-100
(PBS-T). Sections were then incubated overnight at room temperature with the primary anti-
body solution containing rabbit polyclonal anti-VEGF IgG (Santa Cruz Biotechnology, Dallas,
TX, USA; sc-507, 1:100) prepared in PBS-T with 5% of normal horse serum. After several
rinses in PBS-T, sections were incubated for 2 hours in a biotinylated secondary antibody in
PBS-T (biotinylated horse anti-rabbit IgG; Vector Labs, Burlingame, CA, USA; BA-110,
1:500), washed again and finally transferred for 45 minutes to a solution containing streptavi-
din-Cy2 (Jackson ImmunoResearch, West Grove, PA, USA; 016-220-084, 1:400).
In alternate sections of the same animals, immunohistochemistry against Flk-1 was per-
formed. Sections were incubated for 45 minutes in a blocking solution consisting of 10% nor-
mal donkey serum in PBS-T, and then they were incubated for 3 hours at room temperature
with the primary antibody solution containing mouse monoclonal anti-Flk-1 IgG (Santa Cruz
Biotechnology; sc-6251, 1:1000) prepared in PBS-T with 5% of normal donkey serum. After
several rinses in PBS-T, sections were incubated for 2 hours in the secondary antibody solution
(donkey anti-mouse-FITC IgG; Jackson ImmunoResearch; 715-095-150, 1:50).
In order to identify cranial motoneurons in the brainstem, subsequent immunohistochem-
istry for the detection of ChAT was performed in all sections. The primary antibody was a goat
polyclonal anti-ChAT IgG from Millipore (Billerica, MA, USA; AB-144P, 1:500) and the anti-
body binding was visualized by incubating tissue with an anti-goat-TRITC IgG (Jackson
ImmunoResearch; 705-025-003, 1:50).
Sections were then washed for several times, mounted on glass slides and coverslipped with
a 0.1 M solution of n-propyl gallate prepared in glycerol:PBS (9:1).
Antibody characterization
For positive controls, the immunohistochemistry protocol was performed in brain sections
containing cerebellum and hippocampus, areas previously reported as immunopositive for
VEGF and Flk-1, respectively [23,25,26]. As previously described, Purkinje cells in the cerebel-
lum were immunopositive for VEGF (Fig 1A), meanwhile granular cells in the hippocampus
were immunopositive for Flk-1 (Fig 1D). No blocking peptide for VEGF or Flk-1 was available
by provider. Then negative controls were carried out by omission of the primary antibodies,
resulting in absence of staining in all cases (Fig 1B and 1E). Additional negative controls were
performed after replacing the primary antibody incubation by normal rabbit IgG (Jackson
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Immunoresearch; 011-000-002) or normal mouse IgG (Jackson Immunoresearch; 015-000-
002) at the same concentration than the primary antibody. Again, no specific labeling was
found (Fig 1C and 1F). We have previously described the specificity of ChAT [27] and VEGF
[26] antibodies. The antibody used against Flk-1 receptor selectively detects the presence of
this receptor in neurons, but not in endothelial cells [28].
Confocal microscopy and optical density quantification
In order to analyze differences between brainstem motor nuclei in the number of VEGF- or
Flk-1-immunostained motoneurons, confocal microscopy images of motoneurons were cap-
tured at 40X magnification with a confocal laser-scanning microscope (Zeiss LSM 7 DUO,
Oberkochen, Germany). Different focal planes containing the cell nucleus were scanned by
exciting the FITC or Cy2 fluorophores with 488-nm argon laser and the TRITC with 543-nm
laser. Signal intensity was measured by outlining the soma of individual motoneurons (avoid-
ing the cell nucleus) on images of both sides in every section and calculating the average pixel
intensity (i.e., the optical density) using ImageJ software (NIH) [26]. In order to avoid any bias
against motoneurons with low levels of VEGF or Flk-1 expression, all motoneurons (identified
by ChAT staining) within the focal plane of our confocal images (identified by a clear nucleus
within the soma) were included in the analysis. For background correction, four optical den-
sity readings were taken per image in areas devoid of motoneurons [29]. Then, the optical den-
sity value of every cell was divided by the mean background level determined for the same
image. Motoneurons were considered as immunopositive for VEGF or Flk-1 when they
showed an optical density value at least three times higher than the background level. Data are
Fig 1. Antibody characterization. Confocal microscopy images of rat brain sections through the cerebellum (A-C)
or hyppocampus (D-F) showing immunoreactivity to VEGF and Flk-1 in positive controls (A and D) and negative
controls consisting in the omission of the primary antibody (Ab; B and E), or the tissue pre-incubation with normal
rabbit IgG instead of VEGF (C) and normal mouse IgG instead Flk-1 (F) antibodies. Scale bar: 50 μm.
https://doi.org/10.1371/journal.pone.0178616.g001
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presented as the mean percentage of VEGF- or Flk-1-positive motoneurons (identified by
their ChAT labeling) per nucleus obtained in the different animals (n = 9).
Western blot analysis
Adult rats (n = 12) were decapitated under deep anesthesia, and their brains were removed.
Under microscopic observation, the oculomotor complex (including trochlear and oculomo-
tor nuclei [3]), the facial and the hypoglossal nuclei were dissected. The tissue was homoge-
nized in cold lysis buffer containing a cocktail of protease and phosphatase inhibitors [30],
disrupted by sonication and centrifuged at 13000 rpm for 30 minutes. The supernatants were
isolated and total protein concentrations were determined by the Bradford method [31], using
BSA as a standard. Proteins were diluted in sample buffer and denatured at 95˚C for 6 minutes,
and they were separated by 15% (VEGF) or 7.5% (Flk-1) SDS PAGE (50 μg/lane) and trans-
ferred to PVDF membrane by electroblotting. To reduce nonspecific binding, the membranes
were blocked for 1 hour with 10% BSA, and then blots were incubated overnight at 4˚C in a
solution containing anti-VEGF rabbit polyclonal antibody (Abcam, Cambridge, MA, USA;
ab46154, 1:1000) or anti-Flk-1 rabbit polyclonal antibody (Abcam, Cambridge, MA, USA;
ab11939, 1:1000), diluted in TBS-Tween 0.1% supplied with 5% BSA. After washing three
times with PBS-Tween buffer, the membranes were incubated with horseradish peroxidase-
conjugated anti-rabbit antibody (Vector Labs; PI-1000, 1:200) 1 hour at room temperature.
The immunoreaction was detected using the WesternBright Quantum kit (Advansta, Menlo
Park, CA, USA; K-12042). The chemiluminescence was visualized using a Luminescent Image
Analyzer (LAS-3000, Fuji Photo Film GmbH, Du¨sseldorf, Germany). After washing the mem-
branes for 10 minutes with stripping buffer, blots were reprobed with anti-glyceraldehyde
3-phosphate dehydrogenase (GAPDH) mouse monoclonal antibody (Millipore; MAB374,
1:1000) to ensure equal loading. The density of the immunoreactive bands was quantified by
densitometry using the Multi Gauge software (Fuji Photo Film, Japan). The data were normal-
ized to the GAPDH level for each sample. VEGF or Flk-1 expression in facial and hypoglossal
nuclei was expressed relative to that found in the oculomotor complex for each Western blot.
For positive controls of the antibodies, proteins extractions from rat cerebellum and hippo-
campus were included as positive controls of VEGF and Flk-1 antibodies, respectively.
Statistics
The percentage of VEGF-positive or Flk-1-positive motoneurons per nucleus was compared
between nuclei for the immunostaining experiments. The expression of VEGF and Flk-1 pro-
teins obtained from the Western blots in the oculomotor complex, facial and hypoglossal
nuclei was normalized to the GAPDH level expression, and then the expression level in the
facial and hypoglossal nuclei was indicated relative to the oculomotor complex. Comparisons
between nuclei were made with the program SigmaPlot 11 (Systat Software GmbH, Erkrath,
Germany) by using the one-way ANOVA test followed by post hoc multiple comparisons
(Holm-Sidak method) at a significance level of p< 0.05. Data were expressed as
mean ± standard error of the mean (SEM).
Results
The major aim of the present work has been to determine whether the lower vulnerability to
degeneration observed in extraocular motoneurons [2,3,5,29,32], when compared to other cra-
nial motoneurons, could be explained by a higher trophic support by VEGF, according to
recent evidences linking the deficit in this factor with motoneuron disease [20]. For this pur-
pose, we explored and quantitatively compared the presence of VEGF and the expression of its
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receptor Flk-1 between different populations of cranial motoneurons, by means of immuno-
histochemistry at the confocal microscopy level and Western blot analysis.
Presence of VEGF in brainstem motoneurons
In order to study and quantify the presence of VEGF in brainstem motoneurons, a double
immunohistochemistry protocol was performed. Motoneurons were identified by their posi-
tive immunostaining against ChAT (red color, TRITC) (Fig 2A, 2D and 2G). In addition,
VEGF immunolabeling (in green, Cy2) was also used revealing the presence of this factor in
the soma of extraocular motoneurons, which were located in the abducens, trochlear and ocu-
lomotor nuclei (Fig 2B, 2E and 2H; respectively). The overlay of ChAT and VEGF images
revealed the colocalization of both proteins in the majority of extraocular motoneurons (Fig
2C, 2F and 2I), showing their strong immunoreactivity for VEGF.
In contrast, sections from the same animals showed a faint VEGF immunolabeling in other
cranial motoneurons, like those involved in the control of facial muscles and the tongue,
located in the facial and hypoglossal nuclei, respectively. Fig 3 shows ChAT-immunopositive
facial (Fig 3A) and hypoglossal (Fig 3D) motoneurons whose level of VEGF immunostaining
was very low or absent (Fig 3B and 3E, respectively). As a consequence, the merge of ChAT
and VEGF images yielded very few doubly-labeled motoneurons (Fig 3C and 3F).
VEGF immunoreactivity is higher in extraocular motoneurons than in
other cranial motoneurons
The intensity of VEGF immunolabeling was evaluated by quantifying the optical density
within the motoneuron soma in every motor nucleus included in the present study (abducens,
trochlear, oculomotor, facial and hypoglossal nuclei). We considered a cell positive for VEGF
when its optical density was at least three times higher than the background signal (see Materi-
als and methods for details).
When the percentage of VEGF-immunopositive motoneurons was calculated in each
motor group, we found that the majority of motoneurons within the extraocular motor nuclei
were immunopositive for VEGF (abducens: 79.11 ± 2.44%; trochlear: 80.26 ± 6.53%; oculomo-
tor: 68.43 ± 7.87%), and that there were no statistically significant differences between these
three extraocular nuclei (Fig 4; n = 9 animals).
However, significant differences (p< 0.001; one-way ANOVA test followed by post hoc
Holm-Sidak method) were obtained when extraocular motor nuclei were compared to facial
and hypoglossal nuclei (Fig 4). The percentage of VEGF-immunoreactive motoneurons was
around 30% and similar in both non-extraocular nuclei (facial: 30.18 ± 7.86%; hypoglossal:
34.44 ± 9.30%), with absence of significant differences between both nuclei.
Taken together, these results showed that the level of VEGF in motoneurons of the ocular
motor system was higher than that present in other cranial motoneurons of the adult rat.
Expression of Flk-1 in cranial motoneurons
To evaluate whether the differences observed in VEGF correlated with differences in the
expression of the VEGF receptor Flk-1, we studied the presence of this receptor in the same
motor pools. Double immunofluorescence against ChAT and Flk-1 was performed in the five
cranial motor nuclei previously mentioned and results were analyzed at the confocal micros-
copy level.
In the extraocular motor nuclei (i.e., abducens, trochlear and oculomotor), the vast majority
of motoneurons, identified as ChAT-immunoreactive (Fig 5A, 5D, and 5G) also exhibited Flk-
1 immunostaining (Fig 5B, 5E and 5H), as shown in the merged images (Fig 5C, 5F and 5I).
Higher level of VEGF and Flk-1 in extraocular motoneurons
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However, the presence of this receptor in facial and hypoglossal motoneurons was much
less noticeable. Only a faint immunolabeling against Flk-1 was detectable in a reduced number
of facial and hypoglossal motoneurons, as shown in Fig 6.
The analysis of the optical density of Flk-1 in the extraocular motoneurons revealed a high
proportion of motoneurons positive for the receptor (Fig 7). The percentage of Flk-1-positive
neurons in the extraocular nuclei was 81.46 ± 4.79%, 85.68 ± 2.88%, and 61.72 ± 7.86% for the
abducens, trochlear and oculomotor nucleus, respectively. Again, there were no significant dif-
ferences between these three nuclei regarding Flk-1 presence.
In contrast, the percentage of motoneurons that were Flk-1-positive was much lower in the
non-extraocular nuclei. In this case, only 24.72 ± 11.20% and 15.01 ± 7.87% of the motoneu-
rons in the facial and hypoglossal nuclei were Flk-1-immunopositive, respectively. The differ-
ence in the percentage of Flk-1-immunoreactive motoneurons between extraocular motor
nuclei as compared to facial and hypoglossal nuclei was found significant (one-way ANOVA
followed by post hoc Holm-Sidak method; p< 0.001; n = 9 animals; Fig 7). On the other hand,
the percentages obtained from the two latter groups were similar.
Fig 2. VEGF immunoreactivity in extraocular motoneurons. Confocal microscopy images showing the presence of VEGF in the
motoneurons of the extraocular system of the adult rat (ABD: abducens nucleus; TRO: trochlear nucleus; OCM: oculomotor nucleus).
Extraocular motoneurons, identified by ChAT immunostaining (in red; A, D and G), showed intense immunoreactivity to VEGF (in
green; B, E and H). The right column shows the merged images. Insets illustrate higher magnification images of doubly-labeled
motoneurons in every nucleus. Scale bars = 100 μm (in C for A-C; in F for D-F; in I for G-I). Inset scale bars = 25 μm.
https://doi.org/10.1371/journal.pone.0178616.g002
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Therefore, these findings clearly indicated that the majority of extraocular motoneurons
might be receptive to the molecule VEGF acting through its membrane receptor Flk-1,
whereas other cranial motoneurons of the adult rat scarcely expressed this receptor and, in
comparison, were less responsive to VEGF.
Fig 3. VEGF immunoreactivity in facial and hypoglossal motoneurons. Representative confocal microscopy images of facial and
hypoglossal (HYPO) motoneurons, immunopositive for ChAT (in red; A and D, respectively), showing weak immunoreactivity to VEGF
(in green; B and E, respectively). The right column shows the merged images. Insets illustrate higher magnification images of
motoneurons. Scale bars = 100 μm (in C for A-C; in F for D-F). Inset scale bars = 25 μm.
https://doi.org/10.1371/journal.pone.0178616.g003
Fig 4. VEGF immunoreactivity is higher in extraocular motoneurons than in non-extraocular
brainstem motoneurons. Quantification of the percentage of VEGF-positive motoneurons in cranial motor
nuclei. Note the higher percentage of motoneurons positive for this factor in the ocular motor system, in
contrast to the low number observed in the motoneurons of the facial or lingual motor systems. Data represent
mean ± SEM. The asterisk represents significant differences between groups (one-way ANOVA test followed
by Holm-Sidak method for multiple pairwise comparisons; *, p < 0.001; n = 9 animals).
https://doi.org/10.1371/journal.pone.0178616.g004
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Western blot analysis of VEGF and Flk-1 in cranial motor nuclei
We used Western blotting as a quantitative method to compare the total VEGF and Flk-1 pro-
teins present in homogenized tissue obtained from the different brainstem motor nuclei.
For VEGF, in all cases, one protein band was detected at the molecular weight of 45 kDa
(Fig 8A), corresponding to the VEGF protein [33]. As for the immunocytochemistry, we also
used cerebellum as a positive control for VEGF in the Western blots, obtaining a dense band at
45 kDa (Fig 8A). Densitometric analysis revealed that the basal VEGF amount was signifi-
cantly higher in the oculomotor complex (i.e., the oculomotor and trochlear nuclei together)
compared with facial or hypoglossal nuclei and similar between these two latter motor nuclei
(normalized value of 1 for the oculomotor complex; 0.42 ± 0.12 and 0.47 ± 0.12 for the facial
and hypoglossal nuclei, respectively; p< 0.001; one-way ANOVA test followed by post hoc
Holm-Sidak method) (Fig 8B; n = 6 animals). Therefore, the results of Western blots were con-
sistent with those obtained from the immunohistochemical study.
Fig 5. Flk-1 receptor is extensively distributed in extraocular motor nuclei. The left panel shows confocal images of the abducens
(ABD), trochlear (TRO) and oculomotor (OCM) nuclei, whose motoneurons were identified by means of ChAT immunolabeling (TRICT,
red), and expressed high levels of Flk-1 receptor (FITC, green; second column). The third column represents the overlay of ChAT and
Flk-1 images. Insets show representative motoneurons of each nucleus at higher magnification. Scale bars = 100 μm (in C for A-C; in F
for D-F; in I for G-I). Inset scale bars = 25 μm.
https://doi.org/10.1371/journal.pone.0178616.g005
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The Western blot for Flk-1 showed the presence of two bands of 200 and 230 kDa of molec-
ular weight, the latter corresponding to the mature form of Flk-1 protein [34,35], and therefore
being the one to be analyzed (Fig 8C). As a positive control for Flk-1, the Western blotting of
the hippocampus revealed a clear band at this molecular weight (Fig 8C). The results of the
Fig 6. Facial and hypoglossal motoneurons express low levels of Flk-1 receptor. Confocal microscopy images of facial and
hypoglossal (HYPO) motoneurons (A, D; identified as ChAT-immunopositive) showing low levels of Flk-1 immunoreactivity (B, E). C
and F represent the merge of VEGF and Flk-1 images. Insets show motoneurons of each nucleus at higher magnification. Scale
bars = 100 μm (in C for A-C; in F for D-F). Inset scale bars = 25 μm.
https://doi.org/10.1371/journal.pone.0178616.g006
Fig 7. Extraocular motoneurons express higher levels of Flk-1 receptor than non-extraocular
brainstem motoneurons. The bar chart shows the mean and SEM of the percentage of motoneurons
expressing Flk-1 receptor in each brainstem nucleus. The three extraocular motor nuclei showed significantly
higher percentages of Flk-1-immunopositive motoneurons than the facial or hypoglossal nuclei. Data
represent mean ± SEM. The asterisks represent significant differences between groups (one-way ANOVA
test followed by Holm-Sidak method for multiple pairwise comparisons; *, p < 0.001; n = 9 animals).
https://doi.org/10.1371/journal.pone.0178616.g007
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analysis showed that Flk-1 protein level was significantly lower in facial (0.51 ± 0.11) or hypo-
glossal (0.44 ± 0.12) nuclei compared with the oculomotor complex (normalized value of 1 for
the oculomotor complex; p< 0.001; one-way ANOVA test followed by post hoc Holm-Sidak
method) (Fig 8D; n = 6 animals). No differences were observed in the level of Flk-1 protein
between facial and hypoglossal nuclei. Thus, these results supported those obtained by
immunohistochemistry.
Discussion
The main purpose of this work has been to test whether there is a difference in the availability
of the neurotrophic factor VEGF for motoneurons of the oculomotor system, which are
known to be resistant to degeneration, compared to other cranial motoneurons whose resis-
tance is lower. Therefore, we have quantified the presence of VEGF and its receptor Flk-1 in
the motor nuclei containing extraocular motoneurons, and have compared the results with
those obtained from other brainstem motor nuclei containing the motoneurons that control
facial and tongue muscles, which are vulnerable to degeneration.
Presence of VEGF in motoneurons of the oculomotor, facial and
hypoglossal systems
One of the major findings of the present study is that the percentage of adult rat motoneurons
containing the neurotrophic factor VEGF, known to enhance motoneuronal survival
Fig 8. Western blot analysis of VEGF and Flk-1 proteins in rat cranial nuclei. A. The protein band for
VEGF is shown for the oculomotor (OCM), facial and hypoglossal (HYPO) nuclei of the rat. Cerebellum (CB)
protein extract was included as a positive control for VEGF protein. GAPDH immunoblotting was used as load
control. B. Densitometry data showed a significantly lower amount of VEGF protein in facial and hypoglossal
nuclei as compared with the oculomotor complex (one-way ANOVA test followed by Holm-Sidak method for
multiple pairwise comparisons; differences with respect to OCM: *, p<0.001; n = 6 animals). C. Western blot
for Flk-1 in oculomotor, facial and hypoglossal nuclei of the rat. Hippocampus (HC) protein extract was
included as a positive control for Flk-1 protein. GAPDH immunoblotting was used as load control. D. A
significantly higher amount of Flk-1 protein was quantified in the oculomotor complex as compared with facial
and hypoglossal nuclei (one-way ANOVA test followed by Holm-Sidak method for multiple pairwise
comparisons; differences with respect to OCM: *, p<0.001; n = 6 animals).
https://doi.org/10.1371/journal.pone.0178616.g008
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[21,22,36–39], is higher in extraocular motor nuclei than in other brainstem motor nuclei, in
particular the facial and hypoglossal nuclei. The immunohistochemical study revealed that the
majority of the extraocular motoneurons were positive for VEGF labeling, whereas only few
facial and hypoglossal motoneurons showed VEGF immunoreactivity. Western blot analysis
further corroborated these findings showing that the oculomotor complex presented quantita-
tively higher amounts of total VEGF protein in comparison to facial or hypoglossal nuclei.
Therefore, our data suggest the possibility that the differential VEGF content might be
involved in the dissimilar response of these two groups of brainstem motoneurons to neurode-
generation in motoneuronal maladies, such as ALS.
Previous studies have also reported a weak VEGF immunoreactivity in hypoglossal and
facial motoneurons in control rats, highlighting the importance of VEGF presence in the soma
for maintaining the health of motoneurons in the brainstem and spinal cord [18]. It is still
unknown whether the high content of VEGF in the soma of extraocular motoneurons is due
to endogenous synthesis (if so, VEGF would be acting autocrinally), or alternatively VEGF
might reach the motoneurons via either paracrine pathways (e.g., from nearby glial cells), or
retrograde axonal transport from the target muscles, or even anterogradelly from their
afferences.
In neurodegenerative diseases there is a selective preservation of certain brainstem moto-
neuron pools such as the oculomotor/trochlear, as opposed to the trigeminal, facial and hypo-
glossal nuclei which are involved early in the course of the disease [3,4]. Several hypotheses
have been proposed to explain the differential vulnerability of these motoneuronal popula-
tions. Thus, in contrast to facial and hypoglossal motoneurons, which have relatively low cal-
cium buffering capacity, the oculomotor system is characterized by its wealth in calcium-
binding proteins, particularly parvalbumin [6]. This fact, together with a differential expres-
sion of glutamate receptors between these motoneurons [40,41], has been proposed to prevent
motoneuronal degeneration caused by glutamate overstimulation [2,5].
In fact, one of the main mechanisms that have been related to the neurodegeneration asso-
ciated to ALS pathogenesis is glutamate excitotoxicity. Motoneurons are particularly suscepti-
ble to excitotoxicity because they present a high number of Ca2+-permeable AMPA receptors
[42], compared to other types of neurons. Only AMPA receptors lacking the GluR2 subunit
are permeable to Ca2+ ions, and motoneurons are relatively deficient in GluR2 [43]; conse-
quently, they have a higher risk of Ca2+ entry. Calcium ions induce the generation of reactive
oxygen species in mitochondria, which damage the motoneurons in which they are produced
[44].
It has been described that VEGF protects motoneurons against excitotoxicity by up-regulat-
ing the transcription of GluR2 subunit [24]. Thus, if extraocular motoneurons express higher
amounts of VEGF, this trophic factor could be contributing to their survival by increasing the
incorporation of GluR2 subunit in the AMPA receptor complex, protecting them from excito-
toxicity. This could be one of the reasons of the lesser vulnerability to neurodegeneration pre-
sented by these specific motoneuron pools compared to other types of motoneuron.
Therefore, the fact that extraocular motoneurons are endowed with higher amounts of VEGF
(present results) could be related to their higher resistance to cell death when they are exposed
to an excitotoxic environment, as has been proposed to occur in ALS [45]. Indeed, several
reports from other investigators have provided evidences about the reduced susceptibility to
excitotoxicity showed by extraocular motoneurons [32,40,46], suggesting that it could be an
important determinant of their resistance to degeneration.
VEGF expression increases in diverse types of neurons (e.g., cortical and hippocampal) in
response to several insults, such as ischemia and seizures, and it has been suggested that VEGF
up-regulation could be involved in the protection against neuronal loss [47,48]. Indeed, low
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levels of VEGF has been detected in the cerebrospinal fluid and in the anterior horn cells of the
spinal cord in ALS patients [33,49,50]. Furthermore, impairing VEGF production through
genetic manipulation results in degeneration of lower motoneurons in the adulthood [20]. It is
important to highlight that our results are consistent with the neuroprotective role of VEGF.
This neurotrophic factor has been proven to have a great therapeutic potential prolonging
motoneuron survival and enhancing motor performance [21,36,50,51]. Accordingly, it repre-
sents a promising molecule for ALS treatment.
ALS pathogenesis is not confined only to motoneurons, but rather increasing evidences
suggest that surrounding non-neuronal cells are also affected and, indeed, they might play an
important role in the alterations observed in motoneurons. Glia is known to express VEGF
receptors and to modulate synaptic transmission [52,53]. Astrocytes have been reported to
modulate the vulnerability of motoneurons to excitotoxicity, influencing the GluR2 expression
in spinal motoneurons [54]. In fact, as VEGF protects motoneurons against excitotoxicity by
up-regulating GluR2 expression [24], then astrocytes could be contributing to the higher resis-
tance of extraocular motoneurons by providing them with VEGF.
Recently, intrathecal delivery of VEGF has been reported to increase the survival of spinal
motoneurons in SOD1G93A mice by activation of the phosphatidyl-inositol-3-kinase (PI3K)
/Akt survival pathway and increasing the level of the anti-apoptotic factor Bcl-2, but also
through the induction of a switch in the microglial phenotype from M1, the pro-inflammatory
state, to M2, the neuroprotective one [55]. Therefore, the higher levels of VEGF shown by the
oculomotor system could be promoting the anti-inflammatory state of the microglial cells sur-
rounding extraocular motoneurons, although this hypothesis has not been proven yet.
Expression of Flk-1 in motoneurons of the oculomotor, facial and
hypoglossal systems
Another important finding of the present work has been to show that a higher percentage of
extraocular motoneurons express Flk-1 when compared with other brainstem motor pools
(i.e., facial and hypoglossal). A higher amount of Flk-1 in oculomotor nuclei was also quanti-
fied by Western blot, in comparison to facial or hypoglossal nuclei. Although stimulation of
VEGFR-1 (the other tyrosine kinase receptor of VEGF) has also been reported to protect neu-
rons in various models of neuronal death [56,57], the neuroprotective properties of VEGF are
mostly mediated by Flk-1 [20,24,58–60]. Ligand binding to Flk-1 leads to autophosphorylation
and subsequent activation of intracellular pathways, including PI3-K, phospholipase C, and
mitogen-activated protein kinase (MEK) [61], whose activation are known to mediate the pro-
tection induced by VEGF against motoneuron death. Furthermore, Flk-1 blockade prevents
the VEGF-mediated protection against motoneuron death both in vivo [39,62,63] and in vitro
[58]. In addition, low levels of this receptor and its transcript have been detected in anterior
horn cells of the spinal cord of ALS patients [33].
Altogether, it can be suggested that the high levels of Flk-1 expression in the motoneurons
of the oculomotor system found in the present study might contribute to their relative resis-
tance to degeneration.
Conclusions
The presence of VEGF and its receptor Flk-1 in extraocular motoneurons suggests that VEGF
could be acting as a neurotrophic factor for these cells. Moreover, the percentage of extraocular
motoneurons containing VEGF or Flk-1, as well as the amount of these proteins, are signifi-
cantly higher than in other brainstem motor pools (i.e., facial and hypoglossal). These differ-
ences in VEGF signaling between ocular and non-ocular motoneurons suggest that VEGF
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may be an important factor for motoneuronal survival and could contribute to the increased
resistance observed in extraocular motoneurons to neurodegenerative diseases, such as ALS.
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